Myeloma Minute: IMF Comedy Celebration - Nov. 5
October 27, 2016
Ray Romano to Host IMF 10th Annual Comedy Celebration - Nov. 5
The IMF’s annual Comedy Celebration will take place on Saturday, November 5 at the Wilshire Ebell Theatre. Actor and comedian Ray Romano returns as “Everybody’s Most-Loved Host,” with featured performers Bill Burr, Jeff Garlin, Dom Irrera, Larry Miller, Kevin Nealon, JB Smoove, and Fred Willard. Proceeds from the event benefit the Peter Boyle Research Fund and support the Black Swan Research Initiative® (BSRI). Renowned actor Peter Boyle died in 2006 after a four-year battle with myeloma. In celebration of the event’s 10th anniversary, the event will honor Loraine Alterman Boyle for her extraordinary work as the event chair over the past 10 years. Since the annual Comedy Celebration began in 2007, the event has raised more than $5 million to support myeloma research. The evening will include a pre-show cocktail reception and silent auction, and a post-show party featuring a live swing band and dancing for VIP ticket holders.
The IMWG's Dr. Maria-Victoria Mateos Featured on ASH 2016 Panel
On Friday, December 2nd in San Diego, Maria-Victoria Mateos, MD, PhD, an esteemed member of the IMF’s International Myeloma Working Group, will participate in a two-part symposia series at the 2016 Annual Meeting of the American Hematology Society. Entitled “Beyond the Guidelines: Investigator Perspectives on Current Cases, Clinical Issues and Ongoing Research in the Management of Lymphoma and Multiple Myeloma,” these live events will be divided into six lymphoma/CLL and five myeloma topic modules. Each will feature discussion of relevant results from the pre-meeting assessment in addition to a faculty member-led review of emerging research and ongoing trials that inform clinical decision-making.
Fall 2016 Edition of Myeloma Today: Updated Guidelines for Disease Assessment and More
The latest edition of Myeloma Today is out with news on the International Myeloma Working Group’s (IMWG) updated guidelines for disease assessment, which incorporate minimal residual disease (MRD) testing. In this article, leading oncologists discuss if MRD testing is ready for the clinic. Also included in this edition are updates on new myeloma drug designations, and information on the new and improved Myeloma Matrix 2.0 Search Tool from Smart Patients. Explore highlights from the recent Myeloma Master Class with Chinese hematologists that the IMF hosted in Los Angeles, the IMF’s Support Group Leaders’ Summit that drew 100 attendees from 68 support groups, and fun photographs from patient-centered fundraising events. Download your copy HERE.
Improving the Lives of Myeloma Patients Around the World
Myeloma doctors in China face a double challenge: patient loads of 40 to 80 visits each day and limited access to new treatments, reports IMF Chairman Dr. Brian Durie. During a visit to Shanghai this past weekend, the IMF team redoubled its collaborative efforts to expand education programs, explore new research, and boost clinical trial activities in China to increase patient access to effective treatment. To read Dr. Durie’s blog, click HERE.
Nurse Leadership Board: Celebrating 10 Years and Establishing Future Strategic Directions
In November 2006, the IMF brought together a group of nurses from leading myeloma institutions to address the need for side effect management as an integral part of myeloma patient care. As a result of this gathering, the Nurse Leadership Board® (NLB) was founded as a professional partnership to represent nurse experts caring for myeloma patients at leading medical centers. In the course of the following 10 years, members of the NLB established an exemplary record of improving the nursing care and self-care of patients with myeloma by educating nurses and patients via consensus publications, symposia, multimedia, and research. Numerous NLB recommendations have become standards of nursing care for myeloma patients. To learn more, see page 9 of the Fall 2016 edition of the IMF newsletter Myeloma Today or visit nurses.myeloma.org.
We Would Like to Thank Our Sponsors: Takeda, Celgene, Amgen, and Bristol-Myers Squibb